Amarin Corporation plc (AMRN)
Class Action & Lead Plaintiff Deadline: December 23, 2021
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Amarin Corporation plc (“Amarin” or the “Company”) (NASDAQ: AMRN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Amarin between December 5, 2018 and June 21, 2021, inclusive (the “Class Period”).
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) there was an increasingly high risk that certain of Amarin's patents would be invalidated; (2) once the District Court invalidated certain of Amarin's patents, there was little to no chance of reversing that ruling; (3) Amarin's litigation was preventing it from effectuating a successful takeover; and (4) Amarin was downplaying the true threat the ongoing ANDA litigation posed to the Company's business and future prospects.
A class action lawsuit has already been filed. You can review a copy of the Complaint and sign the certification form or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Amarin you have until December 23, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.